Nesrin DEMİR, Nafiye Fulya İLHAN, Tamer DEMİR, Ahmet GÖDEKMERDAN

Serum osteoprotegerin (OPG) measurement in Behcet’s disease

Amaç: Son çalışmalar osteoprotegerinin (OPG) özellikle vasküler hastalıkların gelişiminde önemli bir molekül olduğunu göstermektedir. Burada sunulan çalışmanın amacı, Behçet hastalığı ile serum osteoprotegerin düzeyleri arasında bir ilişki olup olmadığını araştırmaktır. Yöntem ve gereç: 25 Behçet hastası ile cins ve yaş olarak uyumlu 20 sağlıklı kontrol çalışmaya dahil edildi. Serum OPG düzeyleri ELISA ile değerlendirildi. Bulgular: Behçetli hastalardaki serum OPG düzeyleri (813,75 ± 11 pg/mL) sağlıklı kontrollerden (655,56 ± 17 pg/mL) anlamlı olarak yüksek bulundu (P = 0,002). Ancak, aktif dönemdeki hastalarla remisyondakiler arasında OPG düzeyleri yönünden anlamlı bir fark yoktu. Sonuç: Behçet hastalarında OPG değerlerinin yüksek bulunması, OPG’nin vaskülitin veya diğer infl amatuar olayların gelişimiyle ilgili olabileceğini göstermektedir. Sonuç olarak, OPG tek başına hasta izleminde kullanılabilecek bir test olarak değerlendilmese de Behçet hastalarında klinik ve laboratuar bulguları desteklemek için yararlı bir gösterge olabilir. Bu sonuçları daha iyi değerlendirmek için detaylı çalışmalara ihtiyaç vardır.

Behçet hastalarında serum osteoprotegerin ölçümü

Aim: Recent studies indicate that osteoprotegerin (OPG) acts as an important molecule in the development of vascular diseases. Th e aim of the present study was to examine the association between serum OPG levels and Behcet’s disease (BD). Materials and methods: Twenty-fi ve patients with BD and 20 healthy control subjects, matched for age and sex, were included in this study. Serum levels of OPG were determined using ELISA. Results: We found that serum levels of OPG were signifi cantly higher in patients with BD than in healthy control subjects (813.75 ± 11 vs. 655.56 ± 17 pg/mL, P = 0.002). Th ere was no diff erence between active patients and those in remission. Conclusion: Collectively, serum OPG levels were increased in BD patients, suggesting that OPG might be linked with the development of vasculitis or other infl ammatory processes. It was determined that OPG cannot be used as a monitoring test by itself; however, it might be a useful marker for supporting clinical and laboratory fi ndings in relation with BD. Further detailed studies are necessary for a more defi nitive evaluation of these results.

PDF

___

1. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through OPG ligand. Nature 1999; 402: 304-09.
2. Anderson MA, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendriticcell function. Nature 1997; 390: 175-79.
3. Kurban S, Mehmetoğlu I. OPG, Rank and Rank Ligand. Turk J Biochem 2007; 32: 178-84.
4. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA and Giachelli CM. OPG is an αvβ3-induced, NF-kB-dependent survival factor for endothelial cells. J Biol Chem 2000; 275:20959-962.
5. Hofb auer LC, Schoppety M, Christz M, Teichmann J, Lange U. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. Rheumatology 2006; 45: 1218-222.
6. Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 854-58.
7. Simonini G, Masi L, Giani T, Piscitelli E, Cimaz R, Vierucci S et al. Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement. Th e Journal of Rheumatology 2005; 11: 2233-38.
8. Kwok SK, Shin YJ, Kim HJ, Kim HS, Kim JY, Yoo SA et al. Circulating osteoprotegerin levels are elevated and correlated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Lupus 2009; 18: 133-38.
9. Ashcroft A J, Carding S.R. RANK ligand and osteoprotegerin: emerging roles in mucosal infl ammation Gut. 2005; 54: 1345-46.
10. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Camilla S et al. Circulating osteoprotegerin levels and longterm prognosis in patients with acute coronary syndromes. Journal of American College of Cardiology 2008; 51: 627-33.